Effects of Transcranial Magnetic Stimulation After Endovascular Treatment for Acute Ischemic Stroke

Xijing Hospital1 site in 1 country60 target enrollmentAugust 2, 2025

ConditionsIschemic Stroke, Acute Endovascular Thrombectomy

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Ischemic Stroke, Acute
Sponsor: Xijing Hospital
Enrollment: 60
Locations: 1
Primary Endpoint: NIHSS at Day 5
Status: Recruiting
Last Updated: 4 months ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a multicenter, randomized, double-blind, sham-controlled trial, to determine the efficacy and safety of cTBS in treating patients with acute ischemic stroke after endovascular treatment.

Registry

clinicaltrials.gov

Start Date

August 2, 2025

End Date

December 31, 2026

Last Updated

4 months ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Xijing Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients with acute anterior circulation ischemic stroke aged between 18 and 80 years old.
•Imaging suggests that the infarction is caused by occlusion of the terminal portion of the internal carotid artery or the M1/M2 segment of the middle cerebral artery.
•A head CT within 24 hours of onset indicates an ASPECT score ≥6, and meets the guideline-recommended criteria for thrombectomy.
•Pre-stroke mRS score is ≤
•NIHSS score before thrombectomy is between 6 and
•With vascular recanalization of mTICI \> 2b/
•Informed consent form signed.

Exclusion Criteria

•Patients with contraindications to TMS treatment, such as those with metallic foreign objects in the head, pacemakers, implantable drug pumps, cochlear implants, etc.;
•Patients with epilepsy, increased intracranial pressure, tumors, acute cerebral hemorrhage, or other severe neurological diseases, and those with severe functional impairment of organs such as the heart, liver, and kidneys;
•Head CT/MRI indicates midline shift or significant mass effect, or patients planned for surgical intervention;
•Head CT/MRI suggests acute cerebral infarction in both sides;
•Patients who are pregnant or breastfeeding;
•Patients with severe mental disorders or dementia who cannot cooperate with follow-up;
•Patients with other severe diseases resulting in an expected survival of less than 90 days;
•Patients who are participating in other interventional clinical studies within 30 days before the start of this study or after the onset of this condition;
•Patients who cannot cooperate with informed consent.

Outcomes

Primary Outcomes

NIHSS at Day 5

Time Frame: 5 days after enrollment

Changes of infarct volumes from baseline to Day 5

Time Frame: 5 days after enrollment

Death

Time Frame: The first 5 days after enrollment

Secondary Outcomes

Intracranial hemorrhage incidence(24h after enrollment)
Early neurological deterioration(3 days after enrollment)
Final infarct volume(5 days after enrollment)
Proportion of patients with mRS 0-2(90 days after enrollment)
Proportion of patients with symptomatic intracranial hemorrhage(90 days after enrollment)
Barthel Index score(90 days after enrollment)
Stroke recurrence(90 days after enrollment)